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Purpose  of the  research:  Accumulating  evidence  supports  the  role  of  the  cannabinoid  system  in  providing
an  antinociceptive  effect  in various  painful  conditions.  This  effect  is  mediated  through  the  Cannabinoid
receptor  1 (CB1R)  expressed  on  nociceptive  afferent  nerve  terminals.  To investigate  whether  this  receptoreywords:
ental pulp
annabinoid system
mmunohistochemistry
plays  a  similar  role  in dental  pain,  we studied  the  presence  and  distribution  of CB1R  in  rat  dental  pulp.
Pulps  from  28  maxillary  molars  were  immunohistochemically  stained  with  an  antibody  against  CB1R.
Principal results:  Of  all tooth  specimens,  CB1R  immunoreactivity  (CB1R-ir)  was  observed  to be associated
with  nerve  ﬁbers  in radicular  pulp  and  was  seen  as  a continuous  network  in the  subodontoblastic  layer.
Major conclusion:  CB1R  was  present  on  nerve  ﬁbers  in  rat  dental  pulp and  possibly  plays  a role  in dental
pain  mechanisms.
 Japan© 2012
. Introduction
Toothache with pulpal origin is one of the common pains in the
rofacial region. In adults, toothache prevalence for a six-month
eriod ranges from 12.2% [1] to 17.7% [2]. Toothache interferes
ith many aspects of normal function, leading patients to utilize a
ombination of self-care and formal care strategies [3].
Various  approaches have been employed to provide pain con-
rol for a number of human painful conditions including pulpal pain.
ne of the most common approaches is to obtain natural extract or
ynthetic compounds that can provide an analgesic effect. Analgesic
roperties of these compounds usually arise from the consequences
f their actions on pain-related receptors or the involvement in
roduction and metabolism of pain mediators or neurotransmit-
ers. One possible candidate is cannabinoid compounds as they
ossess antinociceptive and antihyperalgesic properties through
he cannabinoid system [4]. The term “cannabinoid system” gener-
lly refers to a signaling system consisting of cannabinoid receptors
CBR), endogenous ligands (e.g. anadamide and 2-archidonyl glyc-
rol) as well as enzymes for ligand biosynthesis and inactivation
5]. Two CBRs have, thus far, been described: Cannabinoid receptor
 (CB1R) [6] and Cannabinoid receptor 2 (CB2R) [7]. Both are mem-
ers of the G-protein coupled superfamily. The antinociceptive and
ntihyperalgesic effects of cannabinoids have been initially thought
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to be mediated largely by CB1R since they are blocked by a selective
CB1R antagonist (SR 141716A) [8–10].
Expression of the CB1R is essentially restricted to neurons. It
has been shown to exist in the brain [11] and spinal cord [12].
One study detected CB1Rs in the majority (89%) of dorsal root
ganglia or sensory neurons [13]. Axoplasmic ﬂow of CB1Rs has
been demonstrated in peripheral sensory axons, implying trans-
portation of CB1R from neurons within sensory ganglia to their
peripheral terminals where cannabinoids are presumed to produce
their antinociceptive effects [14].
CB1R antinociceptive effect is derived from the activation of
these receptors leading to the inhibition of adenylyl cyclase [15],
blockage of several voltage-gated Ca-channels [16], and activa-
tion of several K-channels [17]. These then result in inhibition of
pain-related neurotransmitter release and reduction of neuronal
excitability.
Evidence for the important peripheral sites of cannabinoid anal-
gesic effects came from various studies. These studies showed
that peripheral administration of cannabinoids into inﬂamed tis-
sues could attenuate hyperalgesia and allodynia. This peripheral
CB1R activation was  effective at doses producing minimal centrally
mediated side effects [10,18]. Indeed, one study found one com-
pound with a dual CB1R/CB2R agonist proﬁle (∼170-fold preference
for CB1R over CB2R) and restricted central nervous system perme-
ability [19]. This compound does not penetrate the blood–brain
barrier, thereby providing pain relief without the side effects asso-
ciated with central CB1R activation.
One study has illustrated that trigeminal ganglia neurons, a
major component of the dental pain pathway, contain CB1R [20].
Based on this ﬁnding and the well-known information regarding
evier Ltd. All rights reserved.
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he CB1R localization, distribution, and peripheral analgesic effects,
he cannabinoid system could be used for dental pain control.
oreover, this system also involves the analgesic mechanism of
cetaminophen, one of the most common over-the counter anal-
esics [21].
Interestingly, CB1R has recently been demonstrated in human
ental pulp [22]. This strongly suggests that CB1R could be a
herapeutic target for dental pain management. Nevertheless, for
xperiments proving the involvement of CB1R in providing anal-
esic effects especially for dental pain and further testing for the
harmacological properties as an analgesic drug, an appropriate
nimal model should be established. For this reason, we  decided
o investigate the existence of CB1R in rat dental pulp. The ﬁnding
ould assure us that rat teeth could be utilized as experimental
odels for testing CB1R function and serve as a foundation for
uture experiments especially on developing selective peripheral
cting cannabinoid compounds for dental pain.
. Methods
.1. Subjects
Twenty-eight male adult Wistar rats (National Laboratory
nimal Center, Thailand) weighing 150–200 g were used. All exper-
mental procedures were carried out in accordance with the
ational Institute of Health guidelines for the handling and use
f laboratory animals and received approval from the Animal
esearch Committee of Mahidol University.
Rats were euthanized with a lethal dose of choral hydrate by
ntraperitoneal injection, and ﬁxed by intracardiac perfusion of
hosphate buffered saline (PBS), pH 7.4, at room temperature fol-
owed by a ﬁxative 3% formaldehyde (Scharlau Chemie, Sentenat,
pain) in 0.1 M phosphate buffer (pH 7.4), followed by 2.5% glu-
araldehyde (Electron Microscope Science, Hatﬁeld, PA, USA) in
he same buffer for an additional 15 min. After ﬁxation, a cran-
otomy was performed to extract the whole brain to obtain the
ippocampus. Specimens of maxilla containing maxillary molars
ere dissected and soft tissue was removed. The specimens were
mmersed overnight in 10% formalin at 4 ◦C, then washed for 24 h
n running water and demineralized for four to six weeks in 10%
thylenediaminetetraacetic acid (EDTA; Univar, Ajax Finechem,
aren Point, Australia). Each demineralized maxilla was  divided
nto two pieces, each containing a maxillary ﬁrst molar. The
pecimens were then carefully oriented and embedded in paraf-
n. Twenty-eight maxillary ﬁrst molars were investigated in this
tudy.
ig. 1. (A) A positive control tissue shows positive immunoreactivity of Cannabinoid rece
ippocampus. (B) A negative control tissue shows no staining. International 9 (2012) 17– 20
2.2. Immunohistochemistry
Histologic sections of 5 m thickness were cut from the paraf-
ﬁn embedded blocks and mounted on glass slides coated with
aminopropyltriethoxysilane (APES; Sigma Chemical Co., St. Louis,
MO,  USA). Sections were deparafﬁnized and rehydrated. Endoge-
nous peroxidase activity was  blocked with 10-min incubation in
3% H2O2. Antigen retrieval was performed by immersing the sec-
tions in 10 mM citrate buffer pH 6.0 at 37 ◦C for 1 h. After washing
with 0.1% Tween 20 (MERCK-Schuchardt, Hohanbrunn, Germany)
in PBS, the sections were treated with 8% bovine serum albumin
(Sigma Chemical Co.) in PBS for one hour and then treated with
primary antibody for 2 h at room temperature. The primary anti-
body used in this study was against CB1R (Catalog number AB9129,
Millipore Corporation, Temecula, CA, USA) diluted at 1:100 in PBS.
The immunogen of this antibody is a synthetic peptide from the
C-terminal domain of human CB1R. After thorough washing in
0.1% Tween 20 in PBS, biotinylated anti-rabbit and anti-mouse
immunoglobulins and streptavidin conjugated to horseradish per-
oxidase (LSAB®2 system-HRP kit, DakoCytomation, Carpinteria,
CA, USA) were applied to the sections for 30 min each, followed
by three washes of 0.1% Tween 20 in PBS. Color was  developed
in freshly made diaminobenzidine (Sigma Chemical Co). Sections
were washed brieﬂy in running tap water and lightly counter-
stained with Mayer’s hematoxylin.
Negative  controls were performed by omission of the CB1R pri-
mary antibody. Sections of a rat brain containing hippocampus area
were stained at the same run as positive controls for this antibody.
CB1R has been observed surrounding neurons at the hippocam-
pus area [23]. All control sections were processed under the same
conditions as the investigated sections.
3. Results
First, we  used the brain section containing the hippocampus to
test our antibody against CB1R, as it is widely recognized for its
localization and function on the presynaptic terminals of GABAer-
gic interneurons in CA1 pyramidal cell layers of the hippocampus
[13,23–25]. For our study, CB1R-immunoreactivity (ir) in this par-
ticular area was shown as a golden brown staining (Fig. 1A),
whereas no immunoreactivity was found on the negative con-
trol sections (omitted CB1R primary antibody) of the hippocampus
(Fig. 1B). This positive staining also provided us the appropriate
concentration (1:100 dilution) of the antibody against CB1R used
for the remainder of the study.
CB1R-ir was consistently observed in all of 28 molar teeth. CB1R-
ir nerves were seen traveling in bundles within the intrabony canal
(Fig. 2) and continued entering the pulpal cavity. CB1R-ir nerves
ptor 1 as a strong golden brown staining around pyramidal cells of CA1 area of the
S. Mitrirattanakul et al. / Oral Science
F
b
w
n
l
o
p
(
4
r
[
t
t
f
t
w
t
p
o
B
T
t
[
A
t
T
Fig. 2. Positive immunoreactivity of Cannabinoid receptor 1 is detected in the nerve
undle found in maxillary bone.
ere also observed in the radicular pulp (Fig. 3A). In the coro-
al pulp, these ﬁbers formed a plexus in the subodontoblastic
ayer and in the vicinity of the cell-rich zone. Positive staining
f CB1R appeared to be a continuous network in the roof of the
ulp chamber and was particularly developed in the pulp horns
Fig. 3B).
.  Discussion
Our ﬁndings demonstrated the CB1R-ir in rat dental pulp. This
esult is similar to the study in human dental pulp by Beneng et al.
22]. They found CB1R-ir nerve ﬁbers scattered throughout den-
al pulp and often seen in nerve bundles, but they did not observe
he subodontoblastic layer of CB1R positive ﬁbers. One explanation
or this difference is that CB1R labeling is markedly inﬂuenced by
he ﬁxation procedures [26]. In our study we ﬁxed the pulpal tissue
ith an intracardiac perfusion of 3% formaldehyde followed by glu-
araldehyde, whereas their study postﬁxed the frozen sections of
ulpal tissue with 4% (w/v) paraformaldehyde in PBS. In addition,
ur study utilized an antibody against the C-terminal domain while
eneng’s study used an antibody against the N-terminal domain.
he antibodies against N-terminal are unable to recognize a puta-
ive splice variant of CB1R because it has a truncated N-terminus
27,28] and this could affect the number of CB1R-ir ﬁbers detected.
 study in rats using antibodies against the CB1R C-terminal showed
hat positive CB1R-ir was found in both A-delta and C-neurons [29].
his could be a clear explanation for our observation of CB1R-ir in
ig. 3. Positive immunoreactivity of Cannabinoid receptor 1 (A) nerve ﬁber (*) in the radic International 9 (2012) 17– 20 19
mature  dental pulp both in the subodontoblastic layer innervated
by thinly myelinated A-delta and also in the area of pulp core where
unmyelinated C nociceptive ﬁbers are commonly found.
Another possibility for the difference could be due to the matu-
rity of tooth samples used in the study. Our study used fully
erupted rat molars, whereas the study by Beneng et al. used peri-
coronitis third molars with unknown maturity [22]. It has been
demonstrated that the number of nerve ﬁbers and the expression
of various receptors change after eruption [30]. This was  either
as a result of the stage of development or due to exposure to
intra-oral conditions and a response to function. Previous immuno-
histochemical studies in young and old adult rats found dissimilar
results for different neuronal markers. For example, an immunohis-
tochemical study on Calcitonin gene related peptide (CGRP) found
different CGRP immunoreactivity intensities due to molar age and
attrition. However, the staining of neuroﬁlament protein of den-
tal nerves using retrograded labeling with horseradish peroxidase
found that the intensity of nerve endings in molars is the same for
both young and old rats [31]. For this variation of neuronal expres-
sion, it will be interesting to investigate whether CB1R expression
also changes with maturity or increased function.
Another future study should focus on the changes of CB1R
expression in a dental injury model. It has been shown that in
pulpal inﬂammatory processes, sensory nerve ﬁbers respond to
dentin injury by substantial sprouting of their terminal branches
into the adjacent surviving pulp [32]. The extent and duration of
this response are dependent on severity and nature of the injury,
as well as survival of odontoblasts. In case of minor dentin injuries,
primary odontoblasts are not altered, and the sprouting of sensory
nerve ﬁbers runs under the lesion. In contrast, severe injury such
as deep cavity or pulp exposure involving the destruction of pri-
mary odontoblasts results in a reduction of sensory innervation in
the underlying injured pulp and a sprouting of sensory axons in
the neighboring surviving pulp [33]. It will be interesting to inves-
tigate changes in CB1R localization in these two degrees of dental
injury.
Evidence has shown that CB1R located at the presynaptic ter-
minals decreases the release of GABA neurotransmitter in the
hippocampus [34]. While recent studies have shown expression
of important various pain receptors and mediators in dental pulp
[35–37], the interaction of peripheral CB1R with various pain recep-
tors and mediators remains unexamined. Thus, to understand
the role of peripheral CB1R in pulpal pain, the localization and
functional relationships between CB1R and other important pain
receptors and mediators should be investigated. Moreover, the
relationship of CB1R-ir nerve ﬁbers to odontoblasts should also
be investigated since these cells have been implicated as part of
the signal transduction mechanism in dentinal pain and sensitivity
[35,36].
ular pulp (B) a continuous network in the subodontoblastic layer of rat dental pulp.
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. Conclusion
These studies will greatly improve our understanding about this
omplex pulpal pain mechanism, and knowledge obtained will be
reatly beneﬁcial to the improvement in dental pain management
s well as other trigeminal pain conditions.
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